PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23158095-3 2012 Radioimmunotherapy (RIT) with an anti-CD20 antibody linked to iodine-131 or to yttrium-90 has emerged as well-tolerated treatment after induction. Iodine-131 62-72 keratin 20 Homo sapiens 38-42 2666588-8 1989 A fifth patient, whose tumor did not express the CD37 antigen, was treated with 131I-labeled anti-CD20 MoAb 1F5 and achieved a partial response. Iodine-131 80-84 keratin 20 Homo sapiens 98-102 27689933-1 2016 PURPOSE: Directly radioiodinated [131I]-rituximab has been developed as a radioimmunotherapeutic agent in patients with CD20-positive B cell non-Hodgkin"s lymphoma. Iodine-131 34-38 keratin 20 Homo sapiens 120-124 24099423-3 2013 In this article we describe the efficacy of 131I-rituximab in CD20-expressing Raji cells. Iodine-131 44-48 keratin 20 Homo sapiens 62-66 17547519-1 2007 Iodine 131 (I131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope I131. Iodine-131 0-10 keratin 20 Homo sapiens 57-61 21436340-1 2011 Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. Iodine-131 16-28 keratin 20 Homo sapiens 112-116 20590521-2 2010 I-131 tositumomab is a radiommunoconjugate of (131)I and the anti-CD20 monoclonal antibody tositumomab. Iodine-131 0-5 keratin 20 Homo sapiens 66-70 19707321-3 2007 I-131 Tositumomab is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-approved radioimmunotherapeutic drugs for patients with non-Hodgkin"s lymphoma (NHL). Iodine-131 0-5 keratin 20 Homo sapiens 48-52 19707321-3 2007 I-131 Tositumomab is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-approved radioimmunotherapeutic drugs for patients with non-Hodgkin"s lymphoma (NHL). Iodine-131 24-34 keratin 20 Homo sapiens 48-52 20616910-2 2009 Iodine 131 tositumomab ((131)I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated to (131)I, a radioactive beta and gamma emitter. Iodine-131 0-10 keratin 20 Homo sapiens 80-84 17312330-0 2007 High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. Iodine-131 11-15 keratin 20 Homo sapiens 34-38 17396483-1 2007 Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen. Iodine-131 12-22 keratin 20 Homo sapiens 119-123 16940276-1 2006 PURPOSE: To evaluate efficacy and safety of iodine-131 (131I) -rituximab chimeric anti-CD20 antibody radioimmunotherapy in patients with relapsed or refractory indolent non-Hodgkin"s lymphoma (NHL). Iodine-131 44-54 keratin 20 Homo sapiens 87-91 17204712-0 2007 Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin"s lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. Iodine-131 34-38 keratin 20 Homo sapiens 52-56 16940276-1 2006 PURPOSE: To evaluate efficacy and safety of iodine-131 (131I) -rituximab chimeric anti-CD20 antibody radioimmunotherapy in patients with relapsed or refractory indolent non-Hodgkin"s lymphoma (NHL). Iodine-131 56-60 keratin 20 Homo sapiens 87-91 16091197-4 2005 Other studies in indolent NHL suggest that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease and have potential utility as part of initial treatment as well. Iodine-131 86-91 keratin 20 Homo sapiens 61-65 16979436-1 2006 Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin"s lymphoma. Iodine-131 0-10 keratin 20 Homo sapiens 162-166 16979436-1 2006 Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin"s lymphoma. Iodine-131 12-17 keratin 20 Homo sapiens 162-166 15937686-6 2005 Rituximab, a monoclonal chimeric anti-CD20 antibody (IDEC-C2B8), was labelled with 131I using the Iodogen method. Iodine-131 83-87 keratin 20 Homo sapiens 38-42 12899647-1 2003 Iodine-131 tositumomab [B1, Bexxar , iodine-131 anti-B1 antibody] is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen which is found specifically on B lymphocytes. Iodine-131 0-10 keratin 20 Homo sapiens 149-153 16164191-4 2005 Radioimmunotherapy using 131I- and 90Y-labeled anti-CD20 monoclonal antibodies is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade or transformed non-Hodgkin"s lymphoma (NHL), including patients who are refractory to anti-CD20 monoclonal antibody (rituximab) therapy in the United States. Iodine-131 25-29 keratin 20 Homo sapiens 131-135 16164191-4 2005 Radioimmunotherapy using 131I- and 90Y-labeled anti-CD20 monoclonal antibodies is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade or transformed non-Hodgkin"s lymphoma (NHL), including patients who are refractory to anti-CD20 monoclonal antibody (rituximab) therapy in the United States. Iodine-131 25-29 keratin 20 Homo sapiens 131-135 14503945-0 2003 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Iodine-131 0-4 keratin 20 Homo sapiens 10-14 16304400-7 2005 Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well. Iodine-131 95-100 keratin 20 Homo sapiens 70-74 15160923-2 2004 Iodine 131I-Tositumomab (iodine-131-labeled murine anti-CD20 monoclonal antibody; Bexxar) is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy refractory, CD20-positive, low grade or transformed B-cell non-Hodgkin"s lymphomas. Iodine-131 25-35 keratin 20 Homo sapiens 56-60 15160923-2 2004 Iodine 131I-Tositumomab (iodine-131-labeled murine anti-CD20 monoclonal antibody; Bexxar) is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy refractory, CD20-positive, low grade or transformed B-cell non-Hodgkin"s lymphomas. Iodine-131 25-35 keratin 20 Homo sapiens 200-204 12899647-1 2003 Iodine-131 tositumomab [B1, Bexxar , iodine-131 anti-B1 antibody] is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen which is found specifically on B lymphocytes. Iodine-131 101-111 keratin 20 Homo sapiens 149-153 12054068-1 2002 Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular/low-grade and transformed non-Hodgkin"s lymphoma. Iodine-131 8-12 keratin 20 Homo sapiens 49-53 12271407-2 2002 The purpose of this study was to evaluate the distribution and pharmacokinetics of iodine-131 labelled rituximab in humans for radioimmunotherapy of relapsed CD20-positive NHL. Iodine-131 83-93 keratin 20 Homo sapiens 158-162 10410141-8 1999 Furthermore, radionuclides are also employed in the therapy of cancer, such 131I-labeled anti-CD20 antibody for the B-cell lymphoma and 89Sr for the palliation of bone pain caused by prostate and breast cancer metastases. Iodine-131 76-80 keratin 20 Homo sapiens 94-98 11722986-10 2001 Iodine-131, Yttrium-90, and Copper-67 labeled monoclonal antibodies targeting CD-20, CD-22, HLA class II, and other cell surface antigens have been tested and demonstrate higher overall response rates (50-80%) and complete response rates (20-40%) than unlabeled antibodies. Iodine-131 0-10 keratin 20 Homo sapiens 78-83 10585592-0 2000 Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Iodine-131 28-38 keratin 20 Homo sapiens 44-48 10585592-1 2000 Preliminary clinical trials suggest that iodine-131 ((131)I)-labeled anti-CD20 monoclonal antibodies (MAbs) are effective single agents for the treatment of relapsed non-Hodgkin"s B-cell lymphomas. Iodine-131 41-51 keratin 20 Homo sapiens 74-78 10585592-10 2000 Thus, combination regimens containing (131)I-labeled anti-CD20 antibodies and nucleoside analogs or topoisomerase inhibitors appear particularly attractive for future clinical trials. Iodine-131 38-44 keratin 20 Homo sapiens 58-62 10478178-6 1999 131I labeled anti-CD-20 monoclonal antibodies and 131I-MIBG are used for the therapy of lymphoma and pheochromocytoma, respectively. Iodine-131 0-4 keratin 20 Homo sapiens 18-23 9672771-5 1998 Chimeric anti-CD20 antibodies and 131I-labeled anti-CD20 antibodies appear particularly promising, producing response rates of 50% to 95%. Iodine-131 34-38 keratin 20 Homo sapiens 52-56 9779701-0 1998 Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Iodine-131 60-70 keratin 20 Homo sapiens 84-88 9406707-1 1997 BACKGROUND: In treatment of non-Hodgkin"s lymphoma patients with predose-plus-I-131-labeled anti-B1 (anti-CD20) monoclonal antibody, an intratherapy single photon emission computed tomography (SPECT) image is an important part of research estimates of tumor dosimetry. Iodine-131 78-83 keratin 20 Homo sapiens 106-110 7687326-0 1993 Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. Iodine-131 44-48 keratin 20 Homo sapiens 63-67 7687326-2 1993 As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with 131I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed. Iodine-131 87-91 keratin 20 Homo sapiens 121-125 7687326-2 1993 As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with 131I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed. Iodine-131 87-91 keratin 20 Homo sapiens 166-170 7623531-1 1995 25 patients with relapsed B-cell lymphomas were evaluated with trace labelled doses (2.5 mg/kg, 185-370 MBq [5-10 mCi]) of 131I-labelled anti-CD20 (B1) antibody in a phase II trial. Iodine-131 123-127 keratin 20 Homo sapiens 142-146 7623531-6 1995 131I-anti-CD20 (B1) antibody therapy produces complete responses of long duration in most patients with relapsed B-cell lymphomas when given at maximally tolerated doses with autologous stem cell rescue. Iodine-131 0-4 keratin 20 Homo sapiens 10-14